Quick Answer
MANGOCEUTICALS, INC. reported Operating Income Loss of -$7.97 million for the year ending 2024.
- MANGOCEUTICALS, INC. showed an increase of +13.5% in Operating Income Loss from 2023 to 2024.
- This data is from MANGOCEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 20, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$18.7 thousand | Q2 2022: -$327.9 thousand | Q3 2022: -$991.8 thousand | Q1 2023: -$2.56 million | Q2 2023: -$2.29 million | Q3 2023: -$1.80 million | Q1 2024: -$2.37 million | Q2 2024: -$2.17 million | Q3 2024: -$1.76 million | Q1 2025: -$4.85 million | Q2 2025: -$5.27 million | Q3 2025: -$7.54 million.
- Over the full 3 years of available data (2022 to 2024), MANGOCEUTICALS, INC.'s Operating Income Loss has declined by 300.3%.
- Historical annual values: Fiscal year 2024: -$7.97 million | Fiscal year 2023: -$9.22 million | Fiscal year 2022: -$1.99 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: